INIFY LABORATORIES AB Total Assets
INIFY LABORATORIES AB total assets. Based on the latest financial reports, INIFY LABORATORIES AB (WY60) holds total assets worth €204.64 Million EUR (≈ $239.25 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see INIFY LABORATORIES AB (WY60) market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of INIFY LABORATORIES AB (2021–2025)
Total assets of INIFY LABORATORIES AB from 2021 to 2025. This chart illustrates how INIFY LABORATORIES AB's total assets have evolved over time, based on quarterly financial data. See latest INIFY LABORATORIES AB stock price today for real-time trading data and today's change.
INIFY LABORATORIES AB - Asset Composition Analysis
INIFY LABORATORIES AB Total Assets Breakdown (December 2025)
INIFY LABORATORIES AB total assets breakdown as of December 2025. INIFY LABORATORIES AB's total assets of €204.64 Million consist of 48.6% current assets and 51.4% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 40.9% |
| Accounts Receivable | €2.63 Million | 1.9% |
| Inventory | €1.72 Million | 1.2% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €2.19 Million | 1.6% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how INIFY LABORATORIES AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore INIFY LABORATORIES AB (WY60) working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: INIFY LABORATORIES AB's current assets represent 48.6% of total assets in 2025, a decrease from 100.0% in 2021.
- Cash Position: Cash and equivalents constituted 40.9% of total assets in 2025, down from 90.0% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 1.9% of total assets.
INIFY LABORATORIES AB Competitors by Total Assets
Key competitors of INIFY LABORATORIES AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Voxel S.A.
WAR:VOX
|
Poland | zł746.13 Million |
|
Leveljump Healthcare Corp
V:JUMP
|
Canada | CA$18.29 Million |
|
Prodia Widyahusada Tbk PT
JK:PRDA
|
Indonesia | Rp2.57 Trillion |
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$16.78 Billion |
|
Integral Diagnostics Ltd
AU:IDX
|
Australia | AU$1.43 Billion |
|
Australian Clinical Labs Ltd
AU:ACL
|
Australia | AU$562.50 Million |
|
Healius Ltd
AU:HLS
|
Australia | AU$1.77 Billion |
|
Monash Ivf Group Ltd
AU:MVF
|
Australia | AU$512.35 Million |
INIFY LABORATORIES AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.40 | 14.69 | 5.25 |
| Quick Ratio | 1.32 | 14.59 | 5.12 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €8.12 Million | €147.61 Million | €33.26 Million |
INIFY LABORATORIES AB - Advanced Valuation Insights
This section examines the relationship between INIFY LABORATORIES AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.67 |
| Latest Market Cap to Assets Ratio | 0.22 |
| Asset Growth Rate (YoY) | 227.6% |
| Total Assets | €140.55 Million |
| Market Capitalization | $30.74 Million USD |
Valuation Analysis
Below Book Valuation: The market values INIFY LABORATORIES AB's assets below their book value (0.22x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: INIFY LABORATORIES AB's assets grew by 227.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for INIFY LABORATORIES AB (2021–2025)
The table below shows the annual total assets of INIFY LABORATORIES AB from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €140.55 Million ≈ $164.32 Million |
+227.61% |
| 2024-12-31 | €42.90 Million ≈ $50.16 Million |
-53.87% |
| 2023-12-31 | €93.00 Million ≈ $108.73 Million |
-38.87% |
| 2022-12-31 | €152.13 Million ≈ $177.85 Million |
+30383.52% |
| 2021-12-31 | €499.05K ≈ $583.44K |
-- |
About INIFY LABORATORIES AB
INIFY Laboratories AB provides cancer diagnostics services in Sweden. It offers prostate cancer diagnostics services. The company was incorporated in 2021 and is based in Stockholm, Sweden.